Fecal microbiota transplantation significantly improved respiratory failure of amyotrophic lateral sclerosis

References

• Oskarsson B, Gendron TF, Staff NP. Amyotrophic lateral sclerosis: an update for 2018. Mayo Clin Proc. 2018;93(11):1617–12. doi:10.1016/j.mayocp.2018.04.007.
   PubMed Web of Science ®Google Scholar
• Hardiman O, Al-Chalabi A, Chio A, Corr EM, Logroscino G, Robberecht W, Shaw PJ, Simmons Z, van den Berg LH. Amyotrophic lateral sclerosis. Nat Rev Dis Primers. 2017;3(1):17071. doi:10.1038/nrdp.2017.71.
   PubMed Web of Science ®Google Scholar
• Feldman EL, Goutman SA, Petri S, Mazzini L, Savelieff MG, Shaw PJ, Sobue G. Amyotrophic lateral sclerosis. Lancet (London, England). 2022;400(10360):1363–1380. doi:10.1016/S0140-6736(22)01272-7.
   PubMed Web of Science ®Google Scholar
• Nicholson K, Bjornevik K, Abu-Ali G, Chan J, Cortese M, Dedi B, Jeon M, Xavier R, Huttenhower C, Ascherio A. et al. The human gut microbiota in people with amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2021;22(3–4):186–194. doi:10.1080/21678421.2020.1828475.
   PubMed Web of Science ®Google Scholar
• Di Gioia D, Bozzi Cionci N, Baffoni L, Amoruso A, Pane M, Mogna L, Gaggìa F, Lucenti MA, Bersano E, Cantello R. et al. A prospective longitudinal study on the microbiota composition in amyotrophic lateral sclerosis. BMC Med. 2020;18(1):153. doi:10.1186/s12916-020-01607-9.
   PubMed Web of Science ®Google Scholar
• Fang X, Wang X, Yang S, Meng F, Wang X, Wei H, Chen T. Evaluation of the microbial diversity in amyotrophic lateral sclerosis using high-throughput sequencing. Front Microbiol. 2016;7:1479. doi:10.3389/fmicb.2016.01479.
   PubMed Web of Science ®Google Scholar
• Blacher E, Bashiardes S, Shapiro H, Rothschild D, Mor U, Dori-Bachash M, Kleimeyer C, Moresi C, Harnik Y, Zur M. et al. Potential roles of gut microbiome and metabolites in modulating ALS in mice. Nature. 2019;572(7770):474–480. doi:10.1038/s41586-019-1443-5.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Ogbu D, Garrett S, Xia Y, Sun J. Aberrant enteric neuromuscular system and dysbiosis in amyotrophic lateral sclerosis. Gut Microbes. 2021;13(1):1996848. doi:10.1080/19490976.2021.1996848.
   PubMed Web of Science ®Google Scholar
• Abe K, Aoki M, Tsuji S, Itoyama Y, Sobue G, Togo M, Hamada C, Tanaka M, Akimoto M, Nakamura K. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2017;16(7):505–512. doi:10.1016/S1474-4422(17)30115-1.
   PubMed Web of Science ®Google Scholar
• Andrews JA, Jackson CE, Heiman-Patterson TD, Bettica P, Brooks BR, Pioro EP. Real-world evidence of riluzole effectiveness in treating amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2020;21(7–8):509–518. doi:10.1080/21678421.2020.1771734.
   PubMed Web of Science ®Google Scholar
• Bensimon G, Lacomblez L, Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole study group. N Engl J Med. 1994;330(9):585–591. doi:10.1056/NEJM199403033300901.
   PubMed Web of Science ®Google Scholar
• Abe K, Itoyama Y, Sobue G, Tsuji S, Aoki M, Doyu M, Hamada C, Kondo K, Yoneoka T, Akimoto M. et al. Confirmatory double-blind, parallel-group, placebo-controlled study of efficacy and safety of edaravone (MCI-186) in amyotrophic lateral sclerosis patients. Amyotroph Lateral Scler Frontotemporal Degener. 2014;15(7–8):610–617. doi:10.3109/21678421.2014.959024.
   PubMed Web of Science ®Google Scholar
• Writing Group on behalf of the Edaravone (MCI-186) ALS 18 Study Group. Exploratory double-blind, parallel-group, placebo-controlled study of edaravone (MCI-186) in amyotrophic lateral sclerosis (Japan ALS severity classification: grade 3, requiring assistance for eating, excretion or ambulation). Amyotroph Lateral Scler Frontotemporal Degener. 2017;18(sup1):40–48. doi:10.1080/21678421.2017.1361441.
   PubMedGoogle Scholar
• Witzel S, Maier A, Steinbach R, Grosskreutz J, Koch JC, Sarikidi A, Petri S, Günther R, Wolf J, Hermann A. et al. Safety and effectiveness of long-term intravenous administration of edaravone for treatment of patients with amyotrophic lateral sclerosis. JAMA Neurol. 2022;79(2):121–130. doi:10.1001/jamaneurol.2021.4893.
   PubMed Web of Science ®Google Scholar
• Gupta A, Khanna S. Fecal Microbiota Transplantation. JAMA. 2017;318(1):102. doi:10.1001/jama.2017.6466.
   PubMedGoogle Scholar
• Vendrik KEW, Ooijevaar RE, De Jong PRC, Laman JD, van Oosten BW, van Hilten JJ, Ducarmon QR, Keller JJ, Kuijper EJ, Contarino MF. Fecal microbiota transplantation in neurological disorders. Front Cell Infect Microbiol. 2020;10:98. doi:10.3389/fcimb.2020.00098.
   PubMed Web of Science ®Google Scholar
• Mandrioli J, Amedei A, Cammarota G, Niccolai E, Zucchi E, D’Amico R, Ricci F, Quaranta G, Spanu T, Masucci L. et al. FETR-ALS study protocol: a randomized clinical trial of fecal microbiota transplantation in amyotrophic lateral sclerosis. Front Neurol. 2019;10:1021. doi:10.3389/fneur.2019.01021.
   PubMed Web of Science ®Google Scholar
• Lu G, Wen Q, Cui B, Li Q, Zhang F. Washed microbiota transplantation stopped the deterioration of amyotrophic lateral sclerosis: the first case report and narrative review. J Biomed Res. 2022;37(1):1–8. doi:10.7555/JBR.36.20220088.
   PubMed Web of Science ®Google Scholar
• Brooks BR, Miller RG, Swash M, Munsat TL. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2000;1(5):293–299. doi:10.1080/146608200300079536.
   PubMed Web of Science ®Google Scholar
• Ren R, Gao X, Shi Y, Li J, Peng L, Sun G, Wang Z, Yan B, Zhi J, Yang Y. et al. Long-term efficacy of low-intensity single donor fecal microbiota transplantation in ulcerative colitis and outcome-specific gut bacteria. Front Microbiol. 2021;12:742255. doi:10.3389/fmicb.2021.742255.
   PubMed Web of Science ®Google Scholar
• Cedarbaum JM, Stambler N, Malta E, Fuller C, Hilt D, Thurmond B, Nakanishi A. The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS study group (phase III). J Neurol Sci. 1999;169(1–2):13–21. doi:10.1016/S0022-510X(99)00210-5.
   PubMed Web of Science ®Google Scholar
• Beghini F, Mciver LJ, Blanco-Míguez A, Dubois L, Asnicar F, Maharjan S, Mailyan A, Manghi P, Scholz M, Thomas AM. et al. Integrating taxonomic, functional, and strain-level profiling of diverse microbial communities with bioBakery 3. eLife. 2021;10. doi:10.7554/eLife.65088.
   PubMed Web of Science ®Google Scholar
• Caspi R, Altman T, Billington R, Dreher K, Foerster H, Fulcher CA, Holland TA, Keseler IM, Kothari A, Kubo A. et al. The MetaCyc database of metabolic pathways and enzymes and the BioCyc collection of pathway/genome databases. Nucleic Acids Res. 2014;42(Database issue):D459–71. doi:10.1093/nar/gkt1103.
   PubMed Web of Science ®Google Scholar
• Braun AT, Caballero-Eraso C, Lechtzin N. Amyotrophic lateral sclerosis and the respiratory system. Clin Chest Med. 2018;39(2):391–400. doi:10.1016/j.ccm.2018.01.003.
   PubMed Web of Science ®Google Scholar
• Plowman EK, Gray LT, Chapin J, Anderson A, Vasilopoulos T, Gooch C, Vu T, Wymer JP. Respiratory strength training in amyotrophic lateral sclerosis: a double-blind, randomized, multicenter, sham-controlled trial. Neurology. 2023;100(15):e1634–e42. doi:10.1212/WNL.0000000000206830.
   PubMed Web of Science ®Google Scholar
• Bedlack RS, Vaughan T, Wicks P, Heywood J, Sinani E, Selsov R, Macklin EA, Schoenfeld D, Cudkowicz M, Sherman A. How common are ALS plateaus and reversals? Neurology. 2016;86(9):808–812. doi:10.1212/WNL.0000000000002251.
   PubMed Web of Science ®Google Scholar
• Hu N, Shen D, Yang X, Cui L, Liu M. Plateaus and reversals evaluated by different methods in patients with limb-onset amyotrophic lateral sclerosis. J Clin Neurosci. 2022;97:93–98. doi:10.1016/j.jocn.2022.01.016.
   PubMed Web of Science ®Google Scholar
• Vasta R, D’ovidio F, Canosa A, Manera U, Torrieri MC, Grassano M, de Marchi F, Mazzini L, Moglia C, Calvo A. et al. Plateaus in amyotrophic lateral sclerosis progression: results from a population-based cohort. Eur J Neurol. 2020;27(8):1397–1404. doi:10.1111/ene.14287.
   PubMed Web of Science ®Google Scholar
• Hu N, Shen D, Yang X, Cui L, Liu M. The frequency of ALSFRS-R reversals and plateaus in patients with limb-onset amyotrophic lateral sclerosis: a cohort study. Acta Neurol Belg. 2022;122(6):1567–1573. doi:10.1007/s13760-021-01849-1.
   PubMed Web of Science ®Google Scholar
• Harrison D, Mehta P, van Es MA, Stommel E, Drory VE, Nefussy B, van den Berg LH, Crayle J, Bedlack R. “ALS reversals”: demographics, disease characteristics, treatments, and co-morbidities. Amyotroph Lateral Scler Frontotemporal Degener. 2018;19(7–8):495–499. doi:10.1080/21678421.2018.1457059.
   PubMed Web of Science ®Google Scholar
• Spataro R, Bono V, Marchese S, la Bella V. Tracheostomy mechanical ventilation in patients with amyotrophic lateral sclerosis: clinical features and survival analysis. J Neurol Sci. 2012;323(1–2):66–70. doi:10.1016/j.jns.2012.08.011.
   PubMed Web of Science ®Google Scholar
• Lo Coco D, Marchese S, La Bella V, Piccoli T, Lo Coco A. The amyotrophic lateral sclerosis functional rating scale predicts survival time in amyotrophic lateral sclerosis patients on invasive mechanical ventilation. Chest. 2007;132(1):64–69. doi:10.1378/chest.06-2712.
   PubMed Web of Science ®Google Scholar
• Yeung J, Couper K, Ryan EG, Gates S, Hart N, Perkins GD. Non-invasive ventilation as a strategy for weaning from invasive mechanical ventilation: a systematic review and Bayesian meta-analysis. Intensive Care Med. 2018;44(12):2192–2204. doi:10.1007/s00134-018-5434-z.
   PubMed Web of Science ®Google Scholar
• McCombe PA, Henderson RD, Lee A, Lee JD, Woodruff TM, Restuadi R, McRae A, Wray NR, Ngo S, Steyn FJ. Gut microbiota in ALS: possible role in pathogenesis? Expert Rev Neurother. 2019;19(9):785–805. doi:10.1080/14737175.2019.1623026.
   PubMed Web of Science ®Google Scholar
• Kim HS, Son J, Lee D, Tsai J, Wang D, Chocron ES, Jeong S, Kittrell P, Murchison CF, Kennedy RE. et al. Gut- and oral-dysbiosis differentially impact spinal- and bulbar-onset ALS, predicting ALS severity and potentially determining the location of disease onset. BMC Neurol. 2022;22(1):62. doi:10.1186/s12883-022-02586-5.
   PubMed Web of Science ®Google Scholar
• Zhai CD, Zheng JJ, An BC, Huang HF, Tan ZC. Intestinal microbiota composition in patients with amyotrophic lateral sclerosis: establishment of bacterial and archaeal communities analyses. Chin Med J. 2019;132(15):1815–1822. doi:10.1097/CM9.0000000000000351.
   PubMed Web of Science ®Google Scholar
• Dupuis L, Pradat PF, Ludolph AC, Loeffler JP. Energy metabolism in amyotrophic lateral sclerosis. Lancet Neurol. 2011;10(1):75–82. doi:10.1016/S1474-4422(10)70224-6.
   PubMed Web of Science ®Google Scholar
• Manzo E, Lorenzini I, Barrameda D, O’Conner AG, Barrows JM, Starr A, Kovalik T, Rabichow BE, Lehmkuhl EM, Shreiner DD. et al. Glycolysis upregulation is neuroprotective as a compensatory mechanism in ALS. eLife. 2019;8:8. doi:10.7554/eLife.45114.
   Web of Science ®Google Scholar
• Bell SM, Burgess T, Lee J, Blackburn DJ, Allen SP, Mortiboys H. Peripheral glycolysis in neurodegenerative diseases. IJMS. 2020;21(23):8924. doi:10.3390/ijms21238924.
   Google Scholar
• Tang BL. Glucose, glycolysis, and neurodegenerative diseases. J Cell Physiol. 2020;235(11):7653–7662. doi:10.1002/jcp.29682.
   PubMed Web of Science ®Google Scholar
• Chen J, Siliceo SL, Ni Y, Nielsen HB, Xu A, Panagiotou G. Identification of robust and generalizable biomarkers for microbiome-based stratification in lifestyle interventions. Microbiome. 2023;11(1):178. doi:10.1186/s40168-023-01604-z.
   PubMed Web of Science ®Google Scholar
• Wu G, Meininger CJ, Mcneal CJ, Bazer FW, Rhoads JM. Role of L-Arginine in nitric oxide synthesis and health in humans. Adv Exp Med Biol. 2021;1332:167–187. doi:10.1007/978-3-030-74180-8_10.
   PubMed Web of Science ®Google Scholar
• Zhang S, Qian Y, Li Q, Xu X, Li X, Wang C, Cai H, Zhu J, Yu Y. Metabolic and neural mechanisms underlying the associations between gut bacteroides and cognition: a large-scale functional network connectivity study. Front Neurosci. 2021;15:750704. doi:10.3389/fnins.2021.750704.
   PubMed Web of Science ®Google Scholar
• Ham DJ, Caldow MK, Lynch GS, Koopman R. Arginine protects muscle cells from wasting in vitro in an mTORC1-dependent and NO-independent manner. Amino Acids. 2014;46(12):2643–2652. doi:10.1007/s00726-014-1815-y.
   PubMed Web of Science ®Google Scholar
• Latif S, Kang YS. Differences of transport activity of arginine and regulation on neuronal nitric oxide synthase and oxidative stress in amyotrophic lateral sclerosis model cell lines. Cells. 2021;10(12):3554. doi:10.3390/cells10123554.
   PubMed Web of Science ®Google Scholar
• Lee J, Ryu H, Kowall NW. Motor neuronal protection by L-arginine prolongs survival of mutant SOD1 (G93A) ALS mice. Biochem Bioph Res Co. 2009;384(4):524–529. doi:10.1016/j.bbrc.2009.05.015.
   PubMed Web of Science ®Google Scholar